{"entity":{"id":"sim0270","kind":"drug","name":"SIM0270","aka":[],"tldr":"SIM0270 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Simcere Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","summary":"SIM0270 is an investigational agent whose form is not stated in the registry developed by Jiangsu Simcere Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06680921 (A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)), in HR-positive / HER2-negative breast cancer. The largest, NCT06680921, plans to enrol 482 participants (actual) with primary completion expected 2028-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SIM0270","url":"https://clinicaltrials.gov/search?intr=SIM0270"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["simcere"],"institutions":[],"pathways":[],"terms":[],"trials":["simrise"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sim0270/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}],"trial":[{"id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/"}]}}